In short
Clinical trials are investigating LY3848575 in people with painful distal sensory polyneuropathy, a type of nerve damage that can cause pain. The main goal is to see whether LY3848575 can reduce pain better than placebo and to measure safety and other study results.
Key points
- Clinical trials are studying LY3848575 in people with painful distal sensory polyneuropathy, which is a nerve condition that can cause pain. The available trial is a Phase 2 interventional study with 450 participants and is now completed. Researchers compared LY3848575 with placebo to see whether pain scores improved. The main endpoint was the change in average pain intensity measured by the API-NRS scale. The trial focused on whether at least one dose of LY3848575 was better than placebo for pain relief.
Trial overview
The available study of LY3848575 was an interventional trial, which means researchers gave a study treatment and then measured the results. It was a Phase 2 trial and is listed as completed. The trial included 450 participants and studied pain in people with painful distal sensory polyneuropathy.
Who was studied
The study focused on participants with neuropathic pain and distal sensory polyneuropathy. Neuropathic pain is pain caused by nerve damage or nerve problems, and distal sensory polyneuropathy is a nerve condition that often affects the hands or feet and can cause pain. The source data does not give more details about age, sex, or other entry rules.
What the trial measured
The main outcome was the Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS). Baseline means the starting point before treatment, and the API-NRS is a pain score used to track how pain changes over time. The brief summary says the study aimed to show that at least one dose of LY3848575 was better than placebo for pain intensity.
Trial design and treatment comparison
Participants were assigned to LY3848575 given by subcutaneous injection or to a placebo made to match LY3848575. A placebo is a look-alike treatment that does not contain the active study drug and helps researchers compare results fairly. This design helps show whether any pain improvement is linked to LY3848575 rather than to chance or expectations.
What the trial aimed to show
The study aimed to test whether LY3848575 could reduce pain better than placebo in people with painful distal sensory polyneuropathy. This is an important question because the condition can cause long-lasting nerve pain that affects daily life. Because the trial is completed, the main research question is whether the measured pain scores showed a meaningful difference between the study treatment and placebo.